Effect of early dexamethasone on outcomes of COVID-19: A quasi-experimental study using propensity score matching

Abstract

Background: The RECOVERY trial demonstrated that the use of dexamethasone is associated with a 36% lower 28-day mortality in hospitalized patients with COVID-19 on invasive mechanical ventilation. Nevertheless, the optimal timing to start dexamethasone remains uncertain. Methods: We conducted a quasi-experimental study at National Taiwan University Hospital (Taipei, Taiwan) using propensity score matching to simulate a randomized controlled trial to receive or not to receive early dexamethasone (6 mg/day) during the first 7 days following the onset of symptoms. Treatment was standard protocol-based, except for the timing to start dexamethasone, which was left to physicians’ decision. The primary outcome is 28-day mortality. Secondary outcomes include secondary infection within 60 days and fulfilling the criteria of de-isolation within 20 days. Results: A total of 377 patients with COVID-19 were enrolled. Early dexamethasone did not decrease 28-day mortality in all patients (adjusted odds ratio [aOR], 1.03; 95% confidence interval [CI], 0.97e1.10) or in patients who required O2 for severe/critical disease at admission (aOR, 1.05; 95%CI, 0.94e1.18); but is associated with a 24% increase in superinfection in all patients (aOR, 1.24; 95% CI, 1.12e1.37) and a 23% increase in superinfection in patients of O2 for several/critical disease at admission (aOR, 1.23; 95% CI, 1.02e1.47). Moreover, early dexamethasone is associated with a 42% increase in likelihood of delayed clearance of SARSCoV- 2 virus (adjusted hazard ratio, 1.42; 95% CI, 1.01e1.98). Conclusion: An early start of dexamethasone (within 7 days after the onset of symptoms) could be harmful to hospitalized patients with COVID-19.